Bridging Efficacy of Tofacitinib Immediate‐Release to Extended‐Release Formulations for Treatment of Ulcerative Colitis: Application of a Model‐Informed Drug Development Approach

Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). We report a model‐informed drug development approach for bridging efficacy from immediate‐release (IR) to extended‐release (XR) tofacitinib formulations in patients with UC. IR‐XR efficacy bri...

Descripción completa

Detalles Bibliográficos
Autores principales: Mukherjee, Arnab, Tsuchiwata, Shinichi, Chang, Cheng, Nicholas, Timothy, Su, Chinyu, Le, Vu H., Kushner, Joseph, Kulisek, Nicole
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542796/
https://www.ncbi.nlm.nih.gov/pubmed/35560874
http://dx.doi.org/10.1002/cpdd.1106

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542796/
https://www.ncbi.nlm.nih.gov/pubmed/35560874
http://dx.doi.org/10.1002/cpdd.1106

Ejemplares similares